Evidence map›Paper›PMID 40034236›Full record

ArticleInternational journal of cardiology. Cardiovascular risk and prevention2025

Trends and regional variations in chronic ischemic heart disease and lung cancer-related mortality among American adults: Insights from retrospective CDC wonder analysis.

Eman Ali, Hafsah Alim Ur Rahman, Usama Hussain Kamal, Muhammad Ahmed Ali Fahim, Madiha Salman, Afia Salman, Hamza Nawaz Khan, Farah Yasmin, Chmsalddin Alkhas, Afsana Ansari Shaik and 2 more

Abstract read
In one paragraph

Article in International journal of cardiology. Cardiovascular risk and prevention, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Eman AliInstitute: Dow University of Health Sciences, Karachi, Pakistan.
Hafsah Alim Ur RahmanInstitute: Dow University of Health Sciences, Karachi, Pakistan.
Usama Hussain KamalInstitute: Services Institute of Medical Sciences, Lahore, Pakistan.
Muhammad Ahmed Ali FahimInstitute: Dow University of Health Sciences, Karachi, Pakistan.
Madiha SalmanInstitute: Dow Medical College, Dow University of Health Sciences, Karachi Pakistan.
Afia SalmanInstitute: Dow University of Health Sciences, Karachi, Pakistan.
Hamza Nawaz KhanInstitute: Dow University of Health Sciences, Karachi, Pakistan.
Farah YasminInstitute: Yale School of Medicine, New Haven, CT, USA.
Chmsalddin AlkhasInstitute: Cardiovascular Research Department, Harper University Hospital, Detroit, MI, USA.
Afsana Ansari ShaikInstitute: Division of Nephrology and Hypertension, Mayo Clinic Rochester, MN, USA.
Muhammad Sohaib AsgharInstitute: Department of Internal Medicine, AdventHealth Sebring, FL, USA.
M Chadi AlraiesInstitute: Cardiovascular Institute, Detroit Medical Center, DMC Heart Hospital, 311 Mack Ave, Detroit, MI, 48201, USA.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Introduction: Lung cancer remains the leading cause of cancer-related mortality in the United States and shares cardiovascular risk factors with chronic ischemic heart disease (CIHD). However, the cumulative mortality burden of these comorbid conditions is underexplored. This study aims to retrospectively assess mortality trends among American adults with concurrent lung cancer and CIHD. Methods: We utilized death certificate data from the Centers for Disease Control and Prevention's Wide-Ranging Online Data for Epidemiologic Research (CDC WONDER) database, encompassing ICD-10 codes for individuals aged ≥45 years from 1999 to 2020. Age-adjusted mortality rates (AAMRs) per 100,000 population, annual percentage change (APC), and corresponding 95 % confidence intervals (CIs) were calculated. Data were further stratified by year, sex, race, and geographic region (state, rural-urban, and census regions). Results: A total of 214,785 deaths were identified in adults aged ≥45 years with comorbid lung cancer and CIHD. The overall AAMR between 1999 and 2020 was 8.4 per 100,000 (95 % CI: 8.3 to 8.4). AAMRs remained relatively stable from 1999 to 2005 (APC: -0.84 %; 95 % CI: -1.91 to 1.54), followed by a significant decline from 2005 to 2010 (APC: -2.37 %; 95 % CI: -5.58 to -0.61) and from 2010 to 2017 (APC: -4.72 %; 95 % CI: -7.61 to -3.60). A subsequent period of stability was noted between 2017 and 2020 (APC: 0.86 %; 95 % CI: -2.17 to 5.22). In 1999, men had a threefold higher mortality rate compared to women (AAMR: 17.8 vs. 5.7), with a non-significant decline by 2020 (AAMR: 10 vs. 4). Stratification by race/ethnicity revealed that non-Hispanic (NH) Whites exhibited the highest AAMR at 9.3, followed by NH American Indian or Alaska Natives (7.3), NH Blacks (6.8), Hispanic/Latinos (3.3), and NH Asians or Pacific Islanders (3.2). Geographically, AAMRs were highest in the Midwest (9.6), followed by the Northeast (8.8), South (8.4), and West (6.8). Non-metropolitan regions exhibited higher AAMRs compared to metropolitan areas (10.3 vs. 8.0). States in the top 90th percentile, such as West Virginia, Kentucky, Vermont, Ohio, and Rhode Island, had nearly triple the AAMRs compared to states in the lower 10th percentile, including Utah, Nevada, Arizona, New Mexico, and Hawaii. Conclusions: From 1999 to 2020, mortality rates for adults aged ≥45 years with concurrent lung cancer and CIHD declined. The highest AAMRs were observed among men, NH Whites, individuals residing in the Midwest, and non-metropolitan populations. This highlights the need for a more comprehensive and tailored approach to managing these patients moving forward.

Indexed as

CDCIschemic heart diseaseMortality

Identifiers

PMID40034236
PMCPMC11875809

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.